Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
End-of-day quote. End-of-day quote Japan Exchange - 10/22
3841 JPY   -0.93%
10/22PRESS RELEASE : FDA approves Roche's Susvimo, a -2-
DJ
10/22CHUGAI PHARMACEUTICAL : Organizational Changes
PU
10/22CHUGAI PHARMACEUTICAL : Announces 2021 3rd Quarter Results
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Script (including Q&A)

09/13/2021 | 01:12am EDT

CHUGAI PHARMACEUTICAL CO., LTD.

Information Meeting on FoundationOne Liquid CDx

September 9, 2021

Event Summary

[Company Name]

CHUGAI PHARMACEUTICAL CO., LTD.

[Company ID]

4519-QCODE

[Event Language]

JPN

[Event Type]

Special Announcement

[Event Name]

Information Meeting on FoundationOne Liquid CDx

[Fiscal Period]

[Date]

September 9, 2021

[Number of Pages]

59

[Time]

14:00 - 15:33

(Total: 93 minutes, Presentation: 53 minutes, Q&A: 40 minutes)

[Venue]

Dial-in

[Venue Size]

[Participants]

[Number of Speakers]

3

Satoru Ito

Lifecycle Leader Foundation Medicine

Business Department, Foundation Medicine

Unit

Dr. Takayuki Yoshino

Department of

Gastroenterology and Gastrointestinal

Oncology, National Cancer Center Hospital

East (NCCE), Japan

[Analyst Names]*

Fumiyoshi Sakai

Credit Suisse Securities (Japan) Limited

Hidemaru Yamaguchi

Citigroup Global Markets Japan Inc.

Kazuaki Hashiguchi

Daiwa Securities Co. Ltd.

Motoya Kohtani

Nomura Securities Co., Ltd.

*Analysts that SCRIPTS Asia was able to identify from the audio who spoke during Q&A.

Presentation

Support

Japan

03.4405.3160

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

1

Sasai: Thank you for joining us for today's presentation on the FoundationOne Liquid CDx Cancer Genome Profile.

I'm Sasai from the Corporate Communications Department of Chugai Pharmaceutical, and I'll be moderating today's session. Thank you.

In light of the ongoing coronavirus pandemic, today's session will be conducted in the form of a conference call.

The agenda for today's meeting is shown on the screen, and also on the second page of the presentation materials. This is the format our presentation will follow.

Today, we have invited special lecturer Dr. Takayuki Yoshino, Director, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East (NCCE), Japan. I would like to skip the introduction of Dr. Yoshino's background here, as it has been sent to you along with the presentation materials for today.

Q&A session will be taken after all presentations have been completed.

Mr. Ito, Lifecyle Leader at Chugai's Foundation Medicine Unit, will now provide an overview of the FoundationOne Liquid CDx Cancer Genome Profile.

Support

Japan

03.4405.3160

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

2

Ito: Hello, everyone. This is Ito of Chugai Pharmaceutical.

First, I would like to give an overview of the FoundationOne Liquid CDx Cancer Genome Profile product.

First, I would like to explain the significance of the launch of the FoundationOne Liquid CDx Cancer Genome Profile. As you know, the FoundationOne CDx Cancer Genome Profile is a comprehensive cancer genome profile test. It uses tumor cells and tumor tissues as specimens and was approved in Japan at the end of December 2018. It launched in June 2019, followed by the start of contract testing. It has been 2 years since then.

On March 22 of this year, FoundationOne Liquid CDx Cancer Genome Profile became the first comprehensive cancer genome profiling test, or CGP test, to be approved for testing blood samples in Japan. It became eligible for national health insurance coverage on August 1, and we started contract testing the following day.

The launch of the CGP test for blood specimens is significant. Until then, the FoundationOne CDx test could only be used for tumor tissue specimens. This means that the test could not be used on patients in whom a tumor cell specimen could not be obtained, or on an old tumor specimen.

In addition, there are some patients for whom the test was submitted, but the final results were not obtained due to issues such as the quality of the specimen. For these patients, the addition of a new option for cancer genome profiling test is very significant in cancer treatment. This is a very significant step for cancer treatment.

With these 2 products, we are now able to provide support to more patients with solid cancers. These products allow more detailed treatment plans to be made, according to the patient's situation and stage of treatment. This is expected to lead to the advancement of personalized healthcare, a long-held goal of our company.

Support

Japan

03.4405.3160

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

3

Let me give you a brief overview of the test.

A liquid biopsy, FoundationOne Liquid CDx, analyzes cell-free DNA floating in the blood to identify circulating tumor DNA (cfDNA).

It has been suggested in previous papers that the analysis of this data may provide useful information for selecting treatments based on the detected alterations in cancer-related genes. This product has been commercialized and was the first to be approved and covered by national health insurance in Japan.

Support

Japan

03.4405.3160

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 13 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 September 2021 05:11:07 UTC.


© Publicnow 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD.
10/22PRESS RELEASE : FDA approves Roche's Susvimo, a -2-
DJ
10/22CHUGAI PHARMACEUTICAL : Organizational Changes
PU
10/22CHUGAI PHARMACEUTICAL : Announces 2021 3rd Quarter Results
PU
10/22CHUGAI PHARMACEUTICAL : Notice of Revisions to Financial Forecasts
PU
10/22CHUGAI PHARMACEUTICAL : Notice of Revisions to Dividend Forecast for Fiscal Year Ending De..
PU
10/22CHUGAI PHARMACEUTICAL : Construction of New Bio API Plant for Early Clinical Trials to Acc..
PU
10/22CHUGAI PHARMACEUTICAL : 3Q Results (Jan-Sep 2021)
PU
10/22CHUGAI PHARMACEUTICAL : Supplementary Materials
PU
10/22CHUGAI PHARMACEUTICAL : CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)(for the thi..
PU
10/22CHUGAI PHARMACEUTICAL : Supplementary Materials for Consolidated Financial Results for the..
PU
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Financials
Sales 2021 901 B 7 937 M 7 937 M
Net income 2021 274 B 2 411 M 2 411 M
Net cash 2021 438 B 3 860 M 3 860 M
P/E ratio 2021 23,1x
Yield 2021 1,56%
Capitalization 6 316 B 55 539 M 55 640 M
EV / Sales 2021 6,52x
EV / Sales 2022 6,49x
Nbr of Employees 7 555
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 3 841,00 JPY
Average target price 4 696,92 JPY
Spread / Average Target 22,3%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-30.20%55 539
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979